BANGALORE, July 11, 2012 /PRNewswire/ --
Today, more and more countries across the globe are dedicated towards developing a favourable environment for the growth of biopharmaceutical and biosimilar products in their respective markets. The Indian regulatory bodies like the DCGI and the ICMR too are constantly revising their norms and standards to promote clinical trials, and eventually the growth of biotech products in the country. This is largely due to the fact that these bio-products are solutions to some of the most dreaded diseases and require high manufacturing and marketing investments.
With these developments in the background, CPhI Conferences is launching Global Bio-Clinical Trials 2012, a highly anticipated strategic 4-day initiative (25-28 September, Bangalore, India) focused on the challenges pertaining to the conduct of clinical trials for the approval of sensitive biopharmaceuticals and biosimilars drugs. An interactive seminar on 'Emerging Market Regulations - Brazil, China, Russia, LATAM & Malaysia' will take place on 25th September, and an exclusive workshop on PharmacoKinetics/PharmacoDynamics studies on 28th September.
The 2-day conference (26-27 September) will provide solutions to dealing with the current regulatory challenges and guidelines for robust design of clinical trials, economic patient recruitment and retention protocols, latest tool and techniques for clinical data management and medical writing, along with updates on the latest pharmacovigilance trends.
Eminent speakers like Dr Ragunadarao Digumarti (HOD, Oncology, NIZAMS Hyderabad), Mr Solomon Yimam (Assistant Director, Clinical research, US FDA), Mr Scott Laufenberg (Assistant Director(BIMO),US FDA), Dr Arani Chatterjee (VP, Clinical research, Panacea Biotec), Dr YK Gupta (National Scientific Co-ordinator, Pharmacovigilance Programme of India), Dr Sanjeev Hegde (GM, Clinical Development, Piramal Healthcare), Dr Goutam Pujari (VP, Clinical Research Operations, Glenmark Pharmaceuticals), Dr Deven Parmar (CEO & Medical Director, Karmic Life Sciences), Dr Ajay Gautam (Executive Director and Head of Emerging Markets, AstraZeneca, China), Dr Sanish Davis (Director Clinical Pharmacology in Emerging Markets, MSD), Mr Arjun Roy (Head CDM & Biometrics, Ranbaxy) among other industry experts, are already on board to provide the latest updates for development of biopharmaceuticals and biosimilars in their respective organisations.
Global Bio-Clinical Trials 2012 will bring together 100+ regulators, heads of clinical research, clinical operations & clinical R&D, pharmacovigilance, medical affairs, clinical data management and medical doctors from across biopharmaceutical and biosimilars companies across India and the world, to help increase awareness about the latest developments pertaining to clinical trials of bio-products. For more details log on to www.bioclinicaltrials.com/pr
About CPhI India:
CPhI India is a UBM brand, and is the largest and most important meeting place for the Indian pharma industry. Each year CPhI attracts around 850 exhibitors and 30,000 visitors to the show, providing us with an unrivalled reach to all the key decision makers in the Indian Pharma industry. For more information, visit email@example.com
About UBM India:
UBM India is a subsidiary of UBM plc, which is the second largest independent exhibition organiser in the world. It is the largest trade exhibition organiser in India, responsible for 26 exhibitions in different locations across the country. The company is also involved in the organisation of conference programmes throughout India and in the publications of trade journals and magazines. For further details, visit http://www.ubmindia.in.
SOURCE UBM India Pvt. Ltd.